You are now accessing the company's Half-Year Review 2002.
The Half-Year Review is a summary report on the six months to the 30th June 2002, intended for the investor not needing the full detail of the Half-Year Report.
As a summary report, the Half-Year Review does not contain sufficient information to allow as full an understanding of the results and state of affairs of the Group as is provided by the full Half-Year Report.
Forward-looking statements
Under the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in the Half-Year Review, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under Risk Factors in the Operating and Financial Review in the company's Annual Report on Form 20-F for 2001, filed with the US Securities and Exchange Commission.
Updated August 7, 2002 - © 2005 GlaxoSmithKline - All Rights Reserved
Back to top